<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-5773-23
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PARLODEL 2.5 MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BROMOCRIPTINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        54.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sandoz Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G02CB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Parlodel tablets 2.5 mg</p><p>The <strong>active substance</strong> of Parlodel tablets is bromocriptine mesilate. The <strong>other ingredients </strong>are silica colloidal anhydrous, disodium edetate, magnesium stearate, maleic acid, maize starch and lactose.</p><p>Bromocriptine belongs to the group of medicines, known as the ergot alkaloids, derived from a type of fungus.</p><p>Parlodel reduces the release of prolactin, a hormone from the pituitary gland in the brain. After childbirth or abortion, it is normal for prolactin levels in the mother&rsquo;s blood to rise and this causes the breasts to produce milk.</p><p>Parlodel may be used for the following medical conditions:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parkinson&rsquo;s disease.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In patients with non-malignant tumours which release prolactin (prolactinomas).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A condition where the body produces too much growth hormone (acromegaly).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired function of sexual glands in men (oligospermia, loss of libido, impotence) resulting from too high levels of prolactin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prevention or suppression of milk production for medical reasons in women who do not breast-feed.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular or absent menstruation caused by excessive levels of prolactin.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infertility in women resulting from either too high levels of prolactin, polycystic ovary syndrome or cycles without ovulation.</p><p>If you have any questions about how Parlodel works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Parlodel will only be prescribed for you by a doctor. Follow your doctor&rsquo;s instructions carefully.</p><p>&nbsp;</p><p><strong>a. Do not take Parlodel </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> (hypersensitive) to bromocriptine or any of the other ingredients of Parlodel listed at the beginning of this leaflet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are </strong>allergic to medicines containing ergot alkaloids.</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>too high blood pressure (uncontrolled hypertension), or if your blood pressure is too high during or following your pregnancy.<strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>severe heart disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have</strong> symptoms and/or a history of serious psychic disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parlodel should not be used in case of diseases of the coronary vessels (coronary disease), diseases of the blood vessels (especially occlusive diseases of the arteries), heavy cigarette smoking or other nicotine abuse, gastric and duodenal ulcers, gastrointestinal bleeding, severe hepatic dysfunction or blood poisoning and in concomitant use of ergot alkaloids (found in certain drugs for the treatment of migraine or low blood pressure).</p><p>If any of these apply to you, <strong>tell your doctor without taking </strong>Parlodel<strong>.</strong></p><p>&nbsp;</p><p>b. Take special care with Parlodel:</p><p>If any of the following applies to you, <strong>tell your doctor before you take </strong>Parlodel<strong>:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have</strong> had any black stools or stomach ulcers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>experienced excessive drowsiness or if you have unexpectedly fallen asleep.</p><p>If you experience any of the following, <strong>tell your doctor straight away</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you find</strong> yourself suddenly falling asleep.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>unexplained shortness of breath and difficulty in breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have</strong> severe chest pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have </strong>lower back pain, swollen legs and pain when passing urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you </strong>fail to control gambling or if you have increased sexual drive or failure to resist a temptation, urge or impulse. These side-effects have been reported in patients treated with Parlodel. They appear to be related to the dose of Parlodel<strong> </strong>and occur mainly in patients treated with high doses of the medicine. They are usually reversible if the dose of the medicine is reduced or stopped. Patients should seek help from their doctor if they, or their family/caregiver, notice that their behaviour is unusual.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For women after childbirth or abortion:<strong> If you get</strong> severe, progressive or persistent headaches, and/or problems with your eyesight (such as blurred vision).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For prolactinoma patients: <strong>If you have</strong> a sudden watery discharge from your nose. Your doctor may also check regularly for effects of tumour shrinkage.</p><p>c. Taking Parlodel with food and drink</p><p>Parlodel should always be taken with food.</p><p>If you take Parlodel you should not drink alcohol as it may increase your risk to experience side effects.</p><p>&nbsp;</p><p>d. Parlodel and older people</p><p>Parlodel may be used with caution in older people. Follow your doctor&rsquo;s advice.</p><p>&nbsp;</p><p>e. Parlodel and children</p><p>Parlodel can be used to treat prolactinomas and acromegaly in children aged 7 and above. Follow your doctor&rsquo;s advice.</p><p>&nbsp;</p><p>f. Pregnant women</p><p>Your doctor will discuss with you the potential risk of taking Parlodel during pregnancy.</p><p>Ask your doctor, health care provider or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>g. Breast-feeding mothers</p><p>Do not use Parlodel if you are breast-feeding.</p><p>Women who have taken Parlodel after childbirth or abortion have experienced some rare, serious side effects. These include fits, high blood pressure, stroke, heart attack and psychic disorders.</p><p>&nbsp;</p><p>h. Driving and using machines</p><p>It is generally advisable not to drive or operate machines during treatment with Parlodel.</p><p>Parlodel may lower your blood pressure, which may make you feel light-headed or dizzy. Be particularly careful when you drive or when you operate machinery.</p><p>Parlodel may make you feel drowsy or cause you to sometimes find yourself suddenly falling asleep. If this happens, you must not drive or do anything else that requires you to be alert (e.g operate machinery) until you are clear of such problems. Otherwise you may put yourself and others at risk of serious injury or death.</p><p>&nbsp;</p><p>i. Taking other medicines</p><p><strong>Tell your doctor or pharmacist </strong>if you are taking or have recently taken any other medicines. Remember also those not prescribed by a doctor.</p><p>It is especially important that your doctor knows if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Macrolide antibiotics such as erythromycin, josamycin used to treat infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Octreotide (a medicine used to treat growth disorders).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors such as ritonavir, nelfinavir, indinavir, delavirdine used to treat HIV/AIDS.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat fungal infections such as ketoconazole, itraconazole, voriconazole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; So called dopamine antagonists (such as phenothiazines, butyrophenones thioxanthenes, metoclopramide and domperidone) since they may reduce the effect of Parlodel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenylpropanolamine (a medicine used to treat nasal congestion) and bromocriptine (used to treat Parkinson&rsquo;s disease, pituitary tumor).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sumatriptan, a drug used to treat migraine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ergot alkaloids (drugs used to treat migraine and postdelivery bleeding).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For women after childbirth or abortion: medicines that constrict blood vessels after birth, including the ones containing ergot alkaloids such as ergotamine. Their use together with Parlodel is not recommended.</p><p>Please tell your doctor, health care provider or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Parlodel tablets may be broken.</p><p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dosage.</p><p>When and how to take Parlodel</p><p>Parlodel should always be taken with food.</p><p><em>Acromegaly: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to 10-20&nbsp;mg daily depending on clinical response and adverse effects.</p><p><em>Hyperprolactinaemia in males: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to 5-10&nbsp;mg (2-4&nbsp;tablets) daily.</p><p><em>Inhibition of lactation for medical reasons: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) with the morning meal and again with the evening meal on the first day of treatment, followed by 2.5&nbsp;mg (one tablet) twice daily for 14&nbsp;days. To prevent the onset of lactation, treatment should be instituted within a few hours after parturition or abortion, but not before vital signs have stabilised. Slight milk secretion occasionally occurs 2-3&nbsp;days after treatment has been withdrawn. This can be stopped by resuming treatment at the same dosage for a further week.</p><p><em>Incipient puerperal mastitis: </em>Same dosage as for inhibition of lactation (see above). An antibiotic may be added to the regimen as required.</p><p><em>Disorders of the menstrual cycle and female infertility: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily; if this proves inadequate, gradually increase to 2.5&nbsp;mg (one tablet) two or three times daily. Treatment should be continued until the menstrual cycle is normalised and/or ovulation occurs and, if necessary, over several cycles to prevent relapse.</p><p><em>Prolactinomas: </em>1.25 mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to several tablets daily as required for control of plasma prolactin.</p><p><em>Parkinsonism: </em>In order to ensure optimum tolerability, treatment should be started at a small dose of 1.25&nbsp;mg (&frac12;&nbsp;tablet) daily. During the first week, the dose should preferably be taken in the evening. The dosage should then be increased slowly until the lowest effective dose is established. The daily dose should be gradually increased in steps of 1.25&nbsp;mg at weekly intervals; it should be given in two or three divided doses. If a satisfactory therapeutic response is not achieved within 6-8&nbsp;weeks, further dose increases of 2.5&nbsp;mg/day at weekly intervals may be attempted.</p><p>If adverse effects occur during the titration phase, the daily dose should be reduced temporarily for at least one week. It may be increased again once the adverse effects disappear.</p><p>The total daily dose in monotherapy and combination therapy should not exceed 30&nbsp;mg bromocriptine.</p><p>&nbsp;</p><p>Your doctor will tell you exactly how many tablets of Parlodel to take.</p><p>Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose.</p><p>&nbsp;</p><p>How long to take Parlodel</p><p>Continue to take Parlodel as long as your doctor tells you to.</p><p>&nbsp;</p><p>a. If you forget to take Parlodel</p><p>Take it as soon as you remember, but not if this is less than 4 hours before your next dose of Parlodel tablets. Remember to take it with food.</p><p>b. If you take more Parlodel than you should</p><p>&nbsp;If you have accidentally taken too many tablets or capsules of Parlodel <strong>talk to your doctor straight away.</strong> You may require medical attention.</p><p>&nbsp;</p><p>Effects when treatment with Parlodel is stopped</p><p>Do not stop taking Parlodel unless your doctor tells you to. Suddenly stopping Parlodel may result in unwanted side effects, including a very rare reaction called Neuroleptic Malignant Syndrome with symptoms such as stiffness, agitation, very high fever, rapid heart beat, and extreme fluctuations in blood pressure.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, patients treated with Parlodel may experience<em> </em>side effects, although not everybody gets them.</p><p>Some effects could be serious:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heartburn, recurrent stomach pains or black stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; suddenly falling asleep</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained shortness of breath and difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower back pain, swollen legs and pain when passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe, progressive or persistent headaches, and/or problems with your eyesight (such as blurred vision)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms such as muscle stiffness, agitation, very high fever, rapid heart beat and extreme fluctuations in blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a specific heart problem called cardiac valve fibrosis</p><p>If you experience any of these, <strong>tell your doctor straight away</strong>.</p><p>&nbsp;</p><p>Other side effects:</p><p><strong>Common (less than 1 in every 10 people but more than 1 in every 100 people):</strong> headache, drowsiness, dizziness, nasal congestion, nausea, constipation, vomiting.</p><p><strong>Uncommon (less than 1 in every 100 people but more than 1 in every 1000 people):</strong> allergic skin reactions, hair loss, confusion, psychomotor agitation, hallucinations (seeing, hearing, smelling or feeling things that are not there), dryness of the mouth, dyskinesia (difficulty in performing voluntary movements), tiredness, low blood pressure especially when you stand up which may occasionally lead to fainting, leg cramps.</p><p><strong>Rare (less than 1 in every 1000 people):</strong> diarrhoea, pain in the stomach/abdomen, swelling of arms and legs, fast heartbeat, slow heartbeat, irregular heartbeat, shortness of breath or difficulty in breathing, psychotic/psychic disorders, sleep disturbances (insomnia), somnolence, tingling or numbness of the hands or feet (paraesthesia), ringing in the ears.</p><p><strong>Very rare (less than 1 in every 10,000 people):</strong> excessive daytime sleepiness, pale fingers and toes when exposed to cold, failure to control gambling, increased sexual drive.</p><p>In women after childbirth or abortion rare cases of hypertension, myocardial infarction, seizures, stroke, or psychic disorders have been reported. The causal relationship of these effects to Parlodel is however, uncertain.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>If you notice any other side effects not mentioned in this leaflet, please inform your doctor or pharmacist.</p><p><strong>&nbsp;</strong></p><p><strong>Frequency unknown: </strong></p><p>Psychiatric disorders characterised by impulsivity - failure to resist a temptation, urge or impulse that may harm oneself or others.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parlodel tablets: Do not store above 25&deg;C. Protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date shown on the box. <em>The expiry date refers to the last day of that month</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The <strong><em>active substance</em></strong> of Parlodel is bromocriptine mesilate.</p><p>- The <strong><em>other ingredients</em> </strong>are silica colloidal anhydrous, cetylpalmitate, magnesium stearate, maleic acid, maize starch dried, hydroxypropylmethylcellulose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Country specific
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by Novartis Pharmaceutical Company in 01/2013.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي بروموكريبتين إلى مجموعة من الأدوية تُسمَّى قلوانيات الإرجوت، وهي مشتقة من أحد أنواع الفطريات.</p><p>يعمل بارلودِل على تقليل انطلاق البرولاكتين، وهو هرمون تفرزه الغدة النخامية في الدماغ. بعد الولادة أو الإجهاض، من الطبيعي أن ترتفع مستويات البرولاكتين في دم الأم وهذا يؤدي إلى إفراز اللبن من الثديين.</p><p>يمكن استعمال بارلودِل في الحالات الطبية التالية:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض باركنسون.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في المرضى الذين لديهم أورام غير خبيثة تفرز البرولاكتين (برولاكتينوما).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض فيه يفرز الجسم هرمون النمو بأكثر مما ينبغي (داء ضخامة الأطراف)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف وظيفة الغدد الجنسية في الرجال (قلة الحيوانات المنوية، انعدام الشبق، العجز الجنسي) الناتج عن زيادة مستويات البرولاكتين.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منع أو إخماد إفراز اللبن لأسباب طبية في النساء غير المرضعات.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام الطمث أو انقطاعه بسبب زيادة مستويات البرولاكتين.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم الخصوبة في النساء إما بسبب زيادة مستويات البرولاكتين، أو متلازمة التكيسات المتعددة بالمبيض، أو الدورات عديمة التبويض.</p><p>إذا كانت لديك أي أسئلة عن الكيفية التي يعمل بها بارلودِل أو عن سبب وصف هذا الدواء لك، برجاء أن تسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لن يوصف لك بارلودِل إلا بواسطة طبيب. التزم بجميع تعليمات طبيبك بكل دقة.</p><p>&nbsp;</p><p><strong>لا تستعمل بارلودِل</strong></p><p><strong>إذا كانت لديك أرجية</strong> (حساسية مفرطة) تجاه بروموكريبتين أو تجاه أي من المكونات الأخرى في بارلودِل المذكورة في بداية هذه النشرة.</p><p><strong>إذا كانت لديك أرجية</strong> (حساسية مفرطة) تجاه قلوانيات الإرجوت.</p><p>إذا ظننت أن لديك أرجية (حساسية مفرطة) استشر طبيبك.</p><p><strong>إذا كان لديك</strong> ارتفاع شديد في ضغط الدم (ارتفاع في ضغط الدم غير خاضع للسيطرة)، أو إذا كان ضغط دمك مرتفعاً أثناء الحمل أو بعده.</p><p><strong>إذا كان لديك</strong> مرض قلبي شديد.</p><p><strong>إذا كانت لديك</strong> أعراض و/أو تاريخ عن اضطرابات نَفسِيَّـة خطيرة.</p><p>يجب عدم استعمال بارلودِل في حالة مرض الأوعية التاجية (المرض التاجي)، أمراض الأوعية الدموية (خصوصاً داء انسداد الشرايين)، التدخين بكثرة أو الإفراط في استخدام النيكوتين بأي شكل، قرحة في المعدة أو الاثني عشر، نزيف معدي معوي، خلل وظيفي كبدي حاد أو تسمم الدم و عند مصاحبة استعمال قلويدات الأرغوت (يتواجد في أدوية معينة لعلاج الصداع النصفي أو انخفاض ضغط الدم).</p><p>إذا انطبق عليك أي من الأمور المذكورة عاليه، <strong>أخبر طبيبك مع الامتناع</strong> عن استعمال بارلودِل.</p><p>&nbsp;</p><p><strong>يجب توخي الحذر الخاص مع </strong><strong>بارلودِل:</strong></p><p>إذا انطبق عليك أي من الأمور التالية، <strong>أخبر طبيبك قبل أن تستعمل</strong> بارلودِل:</p><p>إذا كان قد حدث لك في أي وقت براز أسود، أو قروح في المعدة.</p><p>إذا كان قد حدث لك نعاس مفرط أو نوم مفاجئ غير متوقَّع.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>إذا حدث لك أي مما يلي، <strong>أخبر طبيبك فوراً</strong>:</p><p>إذا لاحظت أنك تتعرَّض لنوم مفاجئ.</p><p>إذا كان لديك ضيق في التنفس وصعوبة في التنفس بدون سبب واضح.</p><p>إذا كان لديك ألم شديد في الصدر.</p><p>إذا كان لديك ألم في أسفل الظهر، وتورم في الساقين، وألم عند التبول.</p><p>إذا كنت غير قادر أن تقاوم المقامرة، أو إذا شعرت برغبة جنسية زائدة، أو إذا كنت غير قادر أن تقاوم الإغراءات، أو النزوات، أو الرغبات الملحَّة. هذه الآثار الجانبية تم الإبلاغ عنها في المرضى الذين يُعالَجون باستخدام بارلودِل. وهي تبدو مرتبطة بجرعة بارلودِل وتحدث أساساً في المرضى الذين يتلقون جرعات عالية من الدواء. وهي عادةً قابلة للعكس عند تقليل جرعة الدواء أو عند وقفه. يجب على المرضى أن يطلبوا مساعدة الطبيب إذا لاحظوا هم أو إذا لاحظ أفراد أسرتهم أو الشخص الذي يقوم برعايتهم، أن سلوكهم غير طبيعي.</p><p>في النساء بعد الولادة أو الإجهاض: إذا حدث لديك صداع شديد، أو متزايد، أو مستمر، و/أو مشاكل في الإبصار (مثلاً غشاوة في الإبصار).</p><p>في مرضى البرولاكتينوما: إذا حدث لديك إفراز مائي مفاجئ من الأنف. قد يفحصك طبيبك أيضاً بصفة دورية من جهة آثار انكماش الورم.</p><p>&nbsp;</p><p><strong>ج. استعمال بارلودِل مع الطعام والشراب</strong></p><p>يؤخذ بارلودِل دائماً مع الطعام.</p><p>إذا كنت تستعمل بارلودِل يجب أن تمتنع عن شُرب الكحول وذلك لأنه قد يُزيد من مخاطرة حدوث الآثار الجانبية.</p><p>&nbsp;</p><p><strong>د. بارلودِل والأشخاص المسنون</strong></p><p>يمكن استعمال بارلودِل بحذر في الأشخاص المسنين. التزم بتعليمات طبيبك.</p><p>&nbsp;</p><p><strong>هـ. بارلودِل والأطفال</strong></p><p>يمكن استعمال بارلودِل لعلاج أورام البرولاكتينوما ومرض ضخامة الأطراف في الأطفال ابتداء من سن 7 سنوات فأكثر. التزم بتعليمات طبيبك.</p><p>&nbsp;</p><p><strong>و. النساء الحوامل</strong></p><p>سيناقش معك طبيبك المخاطر الممكنة التي قد تترتب على إعطائك بارلودِل أثناء الحمل.</p><p>استشيري طبيبكِ، مقدم الرعاية الصحية أو الصيدلي قبل استعمال أي دواء.</p><p>&nbsp;</p><p><strong>ز. الأمهات المرضعات</strong></p><p>لا تستعملي بارلودِل إذا كنتِ مرضعة.</p><p>حدث لدى النساء اللاتي أخذن بارلودِل بعد الولادة أو الإجهاض بعض الآثار الجانبية النادرة الخطيرة، وتشمل حدوث تشنجات، ارتفاع ضغط الدم، سكتة دماغية، نوبة قلبية، واضطرابات نفسية.</p><p>&nbsp;</p><p><strong>ح. قيادة السيارة وتشغيل الآلات</strong></p><p>يوصَى عادةً بعدم قيادة السيارة أو تشغيل الآلات أثناء استعمال بارلودِل.</p><p>قد يؤدي بارلودِل إلى خفض ضغط دمك مما قد يجعلك تشعر بالدوخة أو الدوار. كن حذراً على نحو خاص عند قيادة السيارة أو عند تشغيل الآلات.</p><p>قد يجعلك بارلودِل تشعر بالنعاس أو قد يجعلك أحياناً تنام فجأة. إذا حدث لك هذا، يجب أن تمتنع عن قيادة السيارة أو أداء أي شيء يتطلب اليقظة (مثل تشغيل الآلات) إلى أن تتخلص من هذه المشاكل، وإلا فإنك قد تعرِّض نفسك والآخرين للإصابة الخطيرة أو الوفاة.</p><p>&nbsp;</p><p><strong>ط. استعمال أدوية أخرى</strong></p><p><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة قصيرة أي أدوية أخرى، ويشمل ذلك الأدوية التي يتم الحصول عليها بدون تذكرة طبية.</p><p>من المهم على نحو خاص أن تخبر طبيبك إذا كنت تستعمل أي من الأدوية التالية:</p><p>المضادات الحيوية من نوع الماكروليد مثل إريثرومايسين، جوسامايسين، التي تُستعمَل لعلاج العدوى.</p><p>أوكتريوتيد (دواء يُستعمَل لعلاج اضطرابات النمو).</p><p>مثبطات البروتياز مثل ريتونافير، نلفينافير، إندينافير، ديلافيردين التي تُستعمَل لعلاج HIV/ الإيدز.</p><p>الأدوية التي تُستعمَل لعلاج العدوى الفطرية مثل كيتوكونازول، إيتراكونازول، فوريكونازول.</p><p>الأدوية التي تُسمى مضادات الدوبامين (مثل فينوثيازين، بيوتيروفينون، ثيوزانثين، ميتوكلوبراميد، دومبيريدون) حيث أنها تخفض تأثير بارلودِل.</p><p>فينيل بروبانولامين (دواء يُستعمَل لعلاج احتقان الأنف) وبروموكريبتين (يُستعمَل لعلاج مرض باركنسون، ورم الغدة النخامية).</p><p>سوماتريبتان، دواء يُستعمَل لعلاج الصداع النصفي.</p><p>في النساء بعد الولادة أو الإجهاض: الأدوية التي تعمل على انقباض الأوعية الدموية بعد الولادة، وتشمل الأدوية المحتوية على قلوانيات الإرجوت مثل إرجوتامين. لا يوصَى باستعمالها مع بارلودِل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أقراص بارلودِل يمكن كسرها.</p><p>التزم بدقة بتعليمات طبيبك. لا تتجاوز الجرعة الموصَى بها.</p><p><strong>&nbsp;</strong></p><p><strong>متى وكيف تستعمل بارلودِل</strong></p><p>&nbsp;</p><p>يجب أن يؤخذ بارلودل دائماً مع الطعام.داء ضخامة الأطراف: 1,25 مجم (نصف قرص) مرتين أو ثلاث يومياً، تُزاد تدريجياً إلى 10-20 مجم يومياً يعتمد على مدى الإستجابة للدواء والأعراض الجانبية.</p><p>هايبربرولاكتنيميا في الرجال: 1,25 مجم (نصف قرص) مرتين أو ثلاث يومياً، تُزاد تدريجياً إلى 5-10 مجم (2-4 قرص) يومياً.</p><p>إخماد إفراز اللبن لأسباب طبية: 1,25 مجم (نصف قرص) مع الأكل في الصباح ومرة أخرى مع الأكل في المساء في أول يوم من العلاج، يليها 2,5 مجم (قرص واحد) مرتين يومياً لمدة 14 يوماً. لمنع ظهور الحليب، يجب البدء بالعلاج خلال بضع ساعات بعد مخاض الولادة أو الإجهاض ، لكن ليس قبل أن تستقر المؤشرات الحيوية. قد يحدث إفراز طفيف في الحليب أحياناً بعد 2-3 أيام من توقف العلاج. يمكن إيقاف ذلك بإكمال العلاج لمدة أسبوع واحد بنفس الجرعة.</p><p>التهاب الثدي النفاسي الإبتدائي: نفس الجرعة المستخدمة لإخماد إفراز اللبن (راجع الأعلى). من الممكن إضافة المضاد الحيوي إلى النظام العلاجي حسب الحاجة.</p><p>عدم انتظام الطمث وعدم الخصوبة في النساء: 1,25 مجم (نصف قرص) مرتين أو ثلاث يومياً، إذا ثبت أنها غير كافية، تُزاد تدريجياً إلى&nbsp; 2,5 مجم (قرص واحد) مرتين إلى ثلاث يومياً. ينبغي إكمال العلاج إلى أن تنتظم الدورة و/أو يظهر التبويض و، عند الضرورة، على مدة دورات لمنع الانتكاس.</p><p>المرضى الذين لديهم أورام غير خبيثة تفرز البرولاكتين (برولاكتينوما): 1,25 مجم (نصف قرص) مرتين أو ثلاث يومياً، تُزاد تدريجياً إلى عدة أقراص يومياً على حسب الحاجة للسيطرة على البرولاكتين في البلازما.</p><p>الشلل الرعاش (باركينسونيسم): من أجل ضمان أفضل تحمل، ينبغي بدء العلاج بجرعة صغيرة 1,25 مجم (نصف قرص) يومياً. خلال الأسبوع الأول، من الأفضل أن تؤخذ الجرعة في المساء. وينبغي بعد ذلك زيادة الجرعة ببطء حتى يتم الوصول إلى أقل جرعة فعالة. &nbsp;ينبغي زيادة الجرعة اليومية بالتدريج على خطوات 1,25 مجم في فترات أسبوعية؛ إذا لم يتم الحصول على استجابة علاجية مُرْضِية خلال 6-8 أسابيع، من الممكن تجربة زيادة إلى&nbsp; 2,5 مجم على فترات أسبوعية.</p><p>إذا ظهرت آثار جانبية خلال فترة معايرة الجرعة، ينبغي تقليل الجرعة اليومية مؤقتاً لمدة لا تقل عن أسبوع. من الممكن زيادة الجرعة مرة أخرى بمجرد أن تختفي الآثار الجانبية.</p><p>يجب أن لا يزيد مجموع الجرعة اليومية في المعالجة أحادية أو متعددة الدواء عن 30 مجم من البروموكريبتين.</p><p>&nbsp;</p><p>سوف يخبرك طبيبك ما هو العدد بالضبط الذي يجب أن تأخذه من أقراص بارلودِل.</p><p>وفقاً لمدى استجابتك للعلاج، سوف يقترح طبيبك أن يعطيك جرعة أكبر أو أقل.</p><p><strong>ما هي مدة استعمال بارلودِل</strong></p><p>استمر في استعمال بارلودِل للمدة التي يوصي بها طبيبك.</p><p>&nbsp;</p><p><strong>أ. إذا نسيت أن تأخذ بارلودِل</strong></p><p>خذ الدواء بمجرد أن تتذكره، ما لم يكن متبقياً أقل من 4 ساعات قبل أن يحين موعد جرعتك التالية من بارلودِل أقراص.</p><p>تذكر أن تأخذ دواءك مع الطعام.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>ب. إذا أخذت بارلودِل بأكثر مما ينبغي</strong></p><p>إذا أخذت على سبيل الخطأ عدداً من أقراص أو كبسولات بارلودِل أكثر مما ينبغي، <strong>اتصل بطبيبك فوراً</strong>، فإنك قد تحتاج إلى رعاية طبية.</p><p>&nbsp;</p><p><strong>ج. الآثار التي تحدث عند وقف استعمال بارلودِل</strong></p><p>لا توقف استعمال بارلودِل ما لم يوصي طبيبك بذلك. إن الوقف المفاجئ لاستعمال بارلودِل قد يؤدي إلى حدوث آثار جانبية غير مرغوبة، وتشمل حدوث تفاعل نادر جداً يُسمى المتلازمة الخبيثة للدواء المضاد للذهان، وأعراضه هي التيبس، والهياج، والحمى العالية جداً، وتسرع ضربات القلب، والتذبذب المفرط في ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، فإن المرضى الذين يستعملون بارلودِل قد يتعرضون لحدوث آثار جانبية، غير أنها لا تحدث لجميع الأشخاص.</p><p>&nbsp;</p><p><strong>بعض الآثار قد تكون خطيرة:</strong></p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حرقة في فم المعدة، آلام متكررة في المعدة، أو براز أسود</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوم مفاجئ</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس غير معروف السبب وصعوبة في التنفس</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في الصدر</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في أسفل الظهر، وتورم في الساقين، وألم عند التبول.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد، أو متزايد، أو مستمر، و/أو مشاكل في الإبصار (مثلاً غشاوة في الإبصار)</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض في شكل تيبس عضلي، وهياج، وحمى عالية جداً، وتسرع ضربات القلب، وتذبذب مفرط في ضغط الدم</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلة محددة في القلب تُسمى التليف القلبي الصمامي</p><p>إذا حدث لك أي من هذه الأمور، <strong>أخبر طبيبك فوراً</strong>.</p><p>&nbsp;</p><p><strong>آثار جانبية أخرى:</strong></p><p><strong>شائعة (أقل من 1 من كل 10 أشخاص ولكن أكثر من 1 من كل 100 شخص):</strong></p><p>صداع، نعاس، دوخة، احتقان الأنف، غثيان، إمساك، قيء.</p><p>&nbsp;</p><p><strong>غير شائعة (أقل من 1 من كل 100 شخص ولكن أكثر من 1 من كل 1000 شخص):</strong></p><p>تفاعلات جلدية أرجية (حساسية)، سقوط الشعر، تشويش، هياج نفسي حركي، هلاوس (إبصار، سماع، شم، أو الإحساس بأشياء غير موجودة)، جفاف الفم، عُسر الحركة (صعوبة في أداء الحركات الإرادية)، تعب، انخفاض ضغط الدم لا سيما عند الوقوف مما قد يؤدي في أحيان قليلة إلى الإغماء، تقلصات في الساق.</p><p>&nbsp;</p><p><strong>نادرة (أقل من 1 من كل 1000 شخص):</strong> إسهال، ألم في المعدة/ البطن، تورم الذراعين والساقين، تسرع ضربات القلب، بطء ضربات القلب، عدم انتظام ضربات القلب، ضيق التنفس أو صعوبة في التنفس، اضطرابات ذهانية/ نفسية، اضطرابات في النوم (أرق)، نعاس، خدر أو تنميل في اليدين أو القدمين (تشوش الحس)، طنين في الأذن.</p><p>&nbsp;</p><p><strong>نادرة جداً (أقل من 1 من كل 10000 شخص):</strong> نعاس مفرط أثناء النهار، شحوب في أصابع اليدين والقدمين عند التعرض للبرد، عدم القدرة على التحكم في المقامرة، زيادة الرغبة الجنسية.</p><p>في النساء بعد الولادة أو الإجهاض، تم الإبلاغ عن حالات نادرة من ارتفاع ضغط الدم، احتشاء عضلة القلب، تشنجات، سكتة دماغية، أو اضطرابات نفسية. غير أنه لم يتم تأكيد وجود علاقة سببية بين هذه الآثار وبين بارلودِل.</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الآثار، <strong>أخبر طبيبك</strong>.</p><p>إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبر طبيبك أو الصيدلي.</p><p><strong>معدل التكرار غير معروف:</strong></p><p>اضطرابات نفسية تتصف بالاندفاع &ndash; عدم القدرة على مقاومة الإغراءات، أو النزوات، أو الرغبات الملحَّة التي قد تؤدي إلى إيذاء النفس أو الآخرين.</p><p>&nbsp;</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، أخبر طبيبك.</p><p>إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي استعماله بعد تاريخ انتهاء الصلاحية المذكور على العلبة.</p><p>بارلودِل أقراص: تُحفَظ في درجة حرارة لا تزيد عن 25&deg;م مع حمايتها من الضوء.</p><p>يُحفَظ في عبوته الأصلية.</p><p>يُحفظ بعيداً عن متناول ومرأى الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>- <em>المادة الفعالة</em></strong> في أقراص بارلودِل هي بروموكريبتين ميسيلات.</p><p>- <strong><em>المكونات الأخرى</em></strong> هي سيليكا غروانية لامائية، داي صوديوم إديتات، ستيارات ماغنسيوم، حمض مالييك، نشا ذرة، لاكتوز.</p><p>&nbsp;</p><p>هذه المعلومات قد تختلف في بعض البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            خاص بالدولة
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ج‌.	تم آخر اعتماد لهذه النَّشرة من قبل شركة نوفارتس للأدوية في تاريخ 01/2013.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Parlodel®, scored tablets containing 2.5 mg bromocriptine. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scored tablets containing 2.5 mg 
For a full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Scored tablets containing 2.5 mg bromocriptine, as bromocriptine mesilate. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Acromegaly: </em></p><p>As an add-on therapy; as an alternative to surgery or radiotherapy in special cases.</p><p><em>Hyperprolactinaemia in males: </em></p><p>Prolactin-induced hypogonadism (oligospermia, loss of libido, impotence).</p><p>Prolactinomas: Conservative treatment of pituitary micro- or macroprolactinomas; pre-surgical reduction of tumour size to facilitate resection; post-surgical inhibition of persistent hyperprolactinaemia.</p><p><em>Inhibition of lactation for medical reasons (e.g. intrapartum loss, stillbirth, HIV infection of the mother): </em></p><p>Prevention or suppression of puerperal lactation; prevention of lactation following abortion; treatment of incipient puerperal mastitis.</p><p>Parlodel is not recommended for the routine prevention or suppression of puerperal breast engorgement, which can be adequately treated with simple analgesics and breast support.</p><p><em>Disorders of the menstrual cycle and female infertility:</em></p><p>Prolactin-induced hyperprolactinaemic and apparently normoprolactinaemic conditions: Amenorrhoea (with or without galactorrhoea), oligomenorrhoea; luteal-phase deficiency; drug-induced hyperprolactinaemic disorders (e.g. due to certain psychotropic or antihypertensive agents).</p><p>Prolactin-independent female infertility: Polycystic ovary syndrome; anovulatory cycles (to supplement anti-oestrogens, e.g. clomifene).</p><p><em>Parkinsonism: </em></p><p>All stages of idiopathic and postencephalitic Parkinson&rsquo;s disease, either as monotherapy or in combination with other antiparkinsonian drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Parlodel should always be taken with food.</p><p><em>Acromegaly: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to 10-20&nbsp;mg daily depending on clinical response and adverse effects.</p><p><em>Hyperprolactinaemia in males: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to 5-10&nbsp;mg (2-4&nbsp;tablets) daily.</p><p><em>Inhibition of lactation for medical reasons: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) with the morning meal and again with the evening meal on the first day of treatment, followed by 2.5&nbsp;mg (one tablet) twice daily for 14&nbsp;days. To prevent the onset of lactation, treatment should be instituted within a few hours after parturition or abortion, but not before vital signs have stabilised. Slight milk secretion occasionally occurs 2-3&nbsp;days after treatment has been withdrawn. This can be stopped by resuming treatment at the same dosage for a further week.</p><p><em>Incipient puerperal mastitis: </em>Same dosage as for inhibition of lactation (see above). An antibiotic may be added to the regimen as required.</p><p><em>Disorders of the menstrual cycle and female infertility: </em>1.25&nbsp;mg (&frac12;&nbsp;tablet) two or three times daily; if this proves inadequate, gradually increase to 2.5&nbsp;mg (one tablet) two or three times daily. Treatment should be continued until the menstrual cycle is normalised and/or ovulation occurs and, if necessary, over several cycles to prevent relapse.</p><p><em>Prolactinomas: </em>1.25 mg (&frac12;&nbsp;tablet) two or three times daily, gradually increasing to several tablets daily as required for control of plasma prolactin.</p><p><em>Parkinsonism: </em>In order to ensure optimum tolerability, treatment should be started at a small dose of 1.25&nbsp;mg (&frac12;&nbsp;tablet) daily. During the first week, the dose should preferably be taken in the evening. The dosage should then be increased slowly until the lowest effective dose is established. The daily dose should be gradually increased in steps of 1.25&nbsp;mg at weekly intervals; it should be given in two or three divided doses. If a satisfactory therapeutic response is not achieved within 6-8&nbsp;weeks, further dose increases of 2.5&nbsp;mg/day at weekly intervals may be attempted.</p><p>If adverse effects occur during the titration phase, the daily dose should be reduced temporarily for at least one week. It may be increased again once the adverse effects disappear.</p><p>In patients exhibiting levodopa-induced motor disturbances, the dosage of levodopa should be reduced before introducing Parlodel. Further gradual reduction of the levodopa dosage may be possible once a satisfactory response to Parlodel has been obtained, with the possibility of complete withdrawal of levodopa in some cases.</p><p>The total daily dose in monotherapy and combination therapy should not exceed 30&nbsp;mg bromocriptine. The adverse pleuropulmonary effects mentioned under &quot;Warnings and precautions&quot; were reported in connection with long-term treatment in which high doses exceeding 20&nbsp;mg daily were given for 6&nbsp;months.</p><p><em>Special dosage recommendations</em></p><p><em>Children and adolescents </em></p><p>The following dosage recommendations apply for children aged 7 and over, and adolescents:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Dosage/administration in children aged 7 and over</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Maximum recommended daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>7-12&nbsp;years</strong></p></td><td style="vertical-align:top"><p><strong>13-18&nbsp;years</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Prolactinomas</em></strong></p></td><td style="vertical-align:top"><p>1.25&nbsp;mg (&frac12;&nbsp;tablet) twice or three times daily; increase gradually to several tablets per day, as needed, to control plasma prolactin.</p></td><td style="vertical-align:top"><p>5 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr><tr><td style="vertical-align:top"><p>Acromegaly</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Initially 1.25&nbsp;mg (&frac12;&nbsp;tablet) twice or three times daily; depending on clinical response and desired efficacy, increase gradually to several tablets per day.</p></td><td style="vertical-align:top"><p>10 mg</p></td><td style="vertical-align:top"><p>10 mg</p></td></tr></tbody></table><p><em>In children and adolescents aged 7-18 years</em>, the use of Parlodel is not recommended for menstrual cycle disorders, female infertility, hyperprolactinaemia in men, incipient puerperal mastitis, inhibition of lactation for medical reasons and Parkinson&#39;s disease, if the need arises.</p><p><em>Children under 7&nbsp;years of age</em></p><p>The use and safety of Parlodel have not yet been investigated.</p><p>There are insufficient data regarding the safety and efficacy of Parlodel in children under 7 years of age. Use in this age group is therefore not recommended.</p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;</em></p><p><em>Elderly patients</em></p><p>In general, dose selection for elderly patients should be cautious, starting at the lowest dose in the dose range in question, in view of the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapies.</p><p><em>Renal impairment</em></p><p>Parlodel has not been studied in renally impaired patients. As bromocriptine and its metabolites are almost exclusively excreted via the liver, it is unlikely that a dose adjustment is necessary in renally impaired patients.</p><p><em>Hepatic impairment</em></p><p>Parlodel has not been studied in hepatically impaired patients. As the elimination of bromocriptine may be delayed in patients with hepatic impairment, dose adjustment may be necessary. Parlodel is contraindicated in severe hepatic impairment (Child Pugh C).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Existing or previous serious psychiatric disorders.
•	Inadequately controlled arterial hypertension, hypertensive disorders during pregnancy (such as eclampsia, preeclampsia or pregnancy-induced hypertension). Postpartum and puerperal hypertension. 
•	Coronary artery disease and other severe cardiovascular conditions.
•	History of cerebrovascular events. 
•	Arterial occlusive disease. 
•	Raynaud’s phenomenon. 
•	Giant-cell arteritis. 
•	temporal arteritis
•	Stomach ulcers, duodenal ulcers, gastrointestinal bleeding.
•	Severe hepatic dysfunction. 
•	Sepsis.
•	Treatment with methylergometrine or other ergot alkaloids. 
•	Concomitant treatment with strong or moderate cytochrome P450 inhibitors (such as itraconazole, voriconazole and clarithromycin; see "Interactions").
•	Nicotine abuse.
•	Hypersensitivity to bromocriptine, to any of the excipients (see "Composition") or to other ergot alkaloids.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blood pressure should be carefully monitored, especially at the start of treatment, and regularly thereafter on Parlodel treatment.</p><p>In the event of hypertension, vasospastic or thrombotic symptoms, severe, increasing or persistent headache (with or without visual disturbances) or other signs of CNS toxicity, treatment should be discontinued immediately and the patient monitored accordingly.</p><p>There have been reports of gastrointestinal bleeding and gastric ulcers. In such cases, Parlodel should be withdrawn. Patients presenting with an active ulcer or with a history of ulcer should be carefully monitored during treatment with Parlodel.</p><p>Impulse control disorders such as pathological gambling, compulsive spending or buying, increased libido, hypersexuality, binge eating and compulsive eating have been reported during treatment with dopamine agonists such as Parlodel. Patients and carers should be made aware of the possible occurrence of such symptoms. Dose reduction or tapered discontinuation of therapy should be considered in patients who develop such symptoms.</p><p>Hypotensive reactions due to a fall in blood pressure occasionally occur during the first few days of treatment and may cause decreased mental alertness.</p><p>&nbsp;</p><p><em>Postpartum and puerperal use</em></p><p>In rare cases, serious adverse effects such as hypertension, myocardial infarction, seizures, stroke and psychiatric disorders have been reported in postpartum women treated with Parlodel for the inhibition of lactation. In some patients, seizure or stroke was preceded by severe headache and/or transient visual disturbances. Although a causal relationship of these events to Parlodel has not been proven, blood pressure must be monitored regularly.</p><p>Particular caution is required in patients either recently treated with or concurrently using drugs that can alter blood pressure, e.g. vasoconstrictors such as sympathomimetics or ergot alkaloids (including ergometrine or methylergometrine). Concomitant use of such drugs in the puerperium is not recommended.</p><p>In some cases, pleural effusions, pleural, pulmonary and retroperitoneal fibrosis and constrictive pericarditis have been reported in parkinsonian patients receiving long-term treatment with high doses of Parlodel. Fibrotic changes also cannot be ruled out when Parlodel is used in indications other than Parkinson&rsquo;s disease. Parkinsonian patients with a history of such conditions should not be treated with Parlodel.</p><p>Unexplained pleuropulmonary changes should therefore be investigated, and consideration given to discontinuing Parlodel. It is advisable to pay attention to relevant manifestations of retroperitoneal fibrosis (e.g. back pain, oedema of the lower limbs, impaired kidney function) in such patients in order to ensure detection of this condition at its early, reversible stage. Parlodel should be withdrawn if retroperitoneal fibrotic changes are diagnosed or suspected. The pleuropulmonary fibrotic changes observed may be associated with fibrotic thickening of the heart valves, as has been the case in patients treated with other ergot alkaloid derivatives.</p><p>Parlodel has been associated with drowsiness and sudden sleep attacks, particularly in patients with Parkinson&rsquo;s disease. There have been very rare reports of sudden sleep attacks during daily activities, without warning signs. Patients must be informed of this. A reduction in dosage, or withdrawal of therapy, must be considered in patients experiencing drowsiness or sudden sleep onset.</p><p><em>Special warnings for the use of Parlodel in patients with pituitary macroadenoma or microadenoma</em></p><p>Since patients with pituitary macroadenoma resulting from compression or destruction of pituitary tissue may also suffer from hypopituitarism, a thorough examination of pituitary function and appropriate substitution therapy should be carried out before using Parlodel. In patients with secondary adrenocortical insufficiency, corticosteroid substitution is essential.</p><p>Tumour growth must be closely monitored in patients with pituitary macroadenoma. Surgery should be considered if there is evidence of tumour expansion.</p><p>Visual field impairment is a known complication of macroprolactinoma. Effective treatment with Parlodel leads to a reduction in hyperprolactinaemia and often to improvement of the visual field. In some patients, however, secondary visual field impairment may develop despite normalised prolactin levels and tumour shrinkage. This is due to mechanical stress exerted on the optic chiasm, which is pulled down into the now partially empty sella when the tumour shrinks. In such cases, the visual field defect may improve on reduction of the dose of Parlodel due to a rise in prolactin levels and some renewed tumour growth. Regular monitoring of visual fields is therefore indicated in patients with macroprolactinoma in order to allow early detection of secondary visual field impairment and adaptation of the dose of Parlodel, if necessary.</p><p>Close monitoring is necessary in adenoma patients who become pregnant during Parlodel therapy. Prolactin-secreting adenomas may expand during pregnancy. In patients with symptoms of considerable prolactinoma expansion, e.g. headache or visual field impairment, Parlodel treatment may be recommenced. In this case, Parlodel therapy often results in tumour shrinkage and rapid improvement of visual field impairment. In severe cases, compression of the optic nerve or other cerebral nerves may necessitate emergency pituitary surgery.</p><p>Cerebrospinal fluid rhinorrhoea has been observed in some patients with prolactin-secreting adenomas treated with Parlodel. The available data suggest that this may result from shrinkage of invasive tumours.</p><p>If women of child-bearing age with conditions not associated with hyperprolactinaemia are treated with Parlodel, the drug should be given in the lowest effective dose necessary to relieve the symptoms. This should prevent prolactin from falling below normal levels, with a consequent impairment of luteal function.</p><p>There is insufficient evidence of efficacy of bromocriptine in the treatment of premenstrual symptoms or benign breast disease. Parlodel is not recommended for treatment of patients with such illnesses.</p><p>Caution is required when using Parlodel in patients with severe renal impairment.</p><p>Infertility may be reversed by treatment with Parlodel. Women of child-bearing age who do not wish to conceive should therefore be advised to use a reliable method of contraception.</p><p>Parlodel tablets contain lactose. Patients with rare hereditary galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take Parlodel.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic interactions</em></p><p>Bromocriptine is both a substrate and an inhibitor of cytochrome P450 (CYP3A).</p><p><em>Influence of other medicinal products on bromocriptine pharmacokinetics</em></p><p>Co-administration of potent or moderate CYP3A4 inhibitors (e.g. itraconazole, voriconazole, fluconazole, clarithromycin, erythromycin, indinavir, nelfinavir, ritonavir or grapefruit juice) can lead to an increase in bromocriptine plasma levels (see &quot;Contraindications&quot;). There are no data on co-administration with weak CYP3A4 inhibitors.</p><p>Concomitant use of bromocriptine and octreotide in acromegalic patients resulted in elevated plasma levels of bromocriptine, and an increased incidence of adverse effects is likely.</p><p>&nbsp;</p><p><em>Influence of bromocriptine on the pharmacokinetics of other medicinal products</em></p><p>Bromocriptine may increase plasma levels of concomitantly administered medicinal products metabolised by CYP3A4. Caution is therefore required when co-administering substances with a narrow therapeutic window, particularly medicinal products that may prolong the QT interval (e.g. amiodarone, imipramine, terbinafine).</p><p>&nbsp;</p><p><em>Pharmacodynamic interactions</em></p><p><em>Ergot alkaloids:</em> Co-administration of methylergometrine or other ergot alkaloids may increase the stimulant effect on dopamine receptors and lead to dopaminergic side effects such as headache, nausea and vomiting (see &quot;Contraindications&quot;).</p><p><em>Sympathomimetic drugs:</em> Co-administration of sympathomimetics and bromocriptine may lead to hypertension and severe headache (see &quot;Warnings and precautions&quot;).</p><p><em>Sumatriptan</em>: Co-administration of sumatriptan may increase the risk of vasospastic reactions due to additive pharmacological effects.</p><p><em>Dopamine receptor antagonists:</em> Since Parlodel exerts its therapeutic effect by stimulating central dopamine receptors, dopamine antagonists such as antipsychotics (phenothiazines, butyrophenones or thioxanthenes), but also metoclopramide and domperidone, may reduce its activity.</p><p><em>Alcohol:</em> The tolerability of Parlodel may be reduced by alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy:</em></p><p>No data are available from clinical studies. Clinical experience in pregnant women exposed to bromocriptine have shown no adverse effects of bromocriptine on pregnancy or on the health of the fetus or neonate.</p><p>Animal studies have not shown any direct or indirect toxicity affecting pregnancy, embryonic development, fetal development and/or postnatal development (see &quot;Preclinical data&quot;).</p><p>Parlodel must be withdrawn as soon as pregnancy is confirmed, except in cases in which continuation of therapy is medically indicated. No increased incidence of abortion has been observed following withdrawal of Parlodel.</p><p>Women with a pituitary adenoma who become pregnant and withdraw Parlodel must be closely monitored throughout the pregnancy (see &quot;Warnings and precautions&quot;).</p><p><em>Breast-feeding:</em></p><p>Bromocriptine inhibits lactation. Parlodel should therefore not be administered to breastfeeding women outside of its specific postpartum indications (<em>inhibition of lactation for medical reasons</em>; see &quot;Indications/Potential uses&quot;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No relevant studies have been carried out. Hypotensive reactions due to a fall in blood pressure may occasionally occur during the first few days of treatment, causing reduced alertness, and particular caution is therefore necessary when driving a vehicle or operating machinery.</p><p>Patients being treated with Parlodel who have experienced drowsiness and/or sudden sleep attacks must be advised not to drive or operate machines, since they may endanger themselves or others. Patients should be informed of this problem and should avoid such activities until the extent to which they are affected by the symptoms is sufficiently clear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects observed in clinical trials with Parlodel and/or during post-marketing are listed below according to MedDRA system organ classes and frequency. The corresponding frequency category for each adverse effect is based on the following convention (CIOMS III): Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), not known (primarily based on spontaneous post-marketing reports; precise frequency cannot be estimated).</p><p><em>Psychiatric disorders</em></p><p><em>Uncommon:</em> Depressive mood, confusion, psychomotor agitation, hallucinations.</p><p><em>Rare:</em> Psychotic disorders.</p><p><em>Unknown: </em>Impulse control disorders such as compulsive gambling (see &quot;Warnings and precautions&quot;).</p><p><em>Nervous system disorders</em></p><p><em>Common:</em> Headache, dizziness, drowsiness.</p><p><em>Uncommon:</em> Dyskinesia.</p><p>Rare: Sleep disorders, paraesthesia.</p><p><em>Very rare:</em> Excessive daytime somnolence, sudden sleep attacks (see &quot;Warnings and precautions&quot;).</p><p><em>Eye disorders</em></p><p>Rare: Visual impairment, blurred vision.</p><p><em>Ear and labyrinth disorders</em></p><p>Rare: Tinnitus.</p><p><em>Cardiac disorders</em></p><p>Rare: Tachycardia, bradycardia, arrhythmia, pericardial effusion, constrictive pericarditis.</p><p><em>Very rare:</em> Cardiac valve fibrosis.</p><p><em>Unknown:</em> Aggravation of angina pectoris.</p><p><em>Vascular disorders</em></p><p><em>Uncommon:</em> Hypotension, orthostatic hypotension (very rarely leading to syncope).</p><p><em>Very rare:</em> Pallor of fingers and toes induced by cold (especially in patients with history of Raynaud&rsquo;s phenomenon).</p><p><em>Respiratory disorders</em></p><p><em>Common:</em> nasal congestion.</p><p>Rare: Dyspnoea, pleurisy, pleural effusion, pleural fibrosis, pulmonary fibrosis.</p><p><em>Gastrointestinal disorders</em></p><p><em>Common:</em> Nausea, vomiting, constipation.</p><p><em>Uncommon:</em> Dry mouth.</p><p>Rare: Abdominal pain, diarrhoea, gastrointestinal ulcer, gastrointestinal haemorrhage, retroperitoneal fibrosis.</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>Uncommon: </em>Allergic dermatitis, alopecia.</p><p><em>Musculoskeletal disorders</em></p><p><em>Uncommon: </em>Muscle spasms.</p><p><em>Renal and urinary disorders</em></p><p><em>Uncommon: </em>Urinary incontinence.</p><p><em>General disorders</em></p><p><em>Rare: </em>Peripheral oedema.</p><p><em>Very rare:</em> A syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal of Parlodel.</p><p>&nbsp;</p><p>In rare cases (in postpartum use of Parlodel to inhibit lactation), hypertension, myocardial infarction, seizures, stroke or psychiatric disorders have been reported (see &quot;Warnings and precautions&quot;).</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>O Toll Free Number: 8001240078</p><p>O Phone: +966112658100<br />O Fax: +966112658107<br /><strong><em>O Email: </em></strong><strong><em>adverse.events@novartis.com</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following may be symptoms of overdose: nausea, vomiting, dizziness, hypotension, postural hypotension, tachycardia, drowsiness, somnolence, lethargy and hallucinations.</p><p>In case of overdose, administration of activated charcoal is recommended. Gastric lavage may be considered if only a very short time has elapsed since oral ingestion. Management of acute intoxication is symptomatic</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Dopamine agonist ATC code: N04BC01</em></p><p><em>Prolactin inhibitor: ATC code: G02CB01</em></p><p><em>Mechanism of action </em></p><p><em>Effect on the adenohypophysis</em></p><p>Following childbirth, prolactin is necessary for the initiation and maintenance of lactation. At other times, however, increased prolactin secretion gives rise to pathological lactation (galactorrhoea) and/or disorders of ovulation and menstruation.</p><p>Parlodel inhibits secretion of the anterior pituitary hormone prolactin without affecting normal levels of other pituitary hormones. It can, however, reduce elevated levels of growth hormone (GH) in patients with acromegaly. These effects are due to stimulation of dopamine receptors.</p><p>The prolactin-lowering action begins to take effect 1-2&nbsp;hours after ingestion, peaks (i.e. brings about a reduction of &gt;&nbsp;80% in plasma prolactin) after 5-10&nbsp;hours and is maintained for 8-12&nbsp;hours.</p><p>As a specific inhibitor of prolactin secretion, Parlodel can be used to prevent or suppress physiological lactation as well as to treat prolactin-induced pathological states. In amenorrhoea and/or anovulation (with or without galactorrhoea), Parlodel can be used to restore menstrual cycles and ovulation.</p><p>Customary measures taken during weaning, such as the restriction of fluid intake, are not necessary with Parlodel. In addition, Parlodel does not impair puerperal involution of the uterus or increase the risk of thromboembolism.</p><p>Parlodel improves the clinical symptoms of polycystic ovary syndrome by restoring a normal pattern of luteinising hormone secretion.</p><p>Parlodel has also been shown to arrest the growth or reduce the size of prolactin-secreting pituitary adenomas (prolactinomas).</p><p>In acromegalic patients, Parlodel has a beneficial effect on clinical symptoms and glucose tolerance, in addition to lowering the plasma levels of growth hormone and prolactin.</p><p><em>Dopaminergic effects</em></p><p>Because of its dopaminergic activity, Parlodel, at doses usually higher than those for its endocrinological indications, is effective in the treatment of Parkinson&#39;s disease, which is characterised by a specific nigrostriatal dopamine deficiency. In this condition, the stimulation of dopamine receptors by Parlodel can restore the neurochemical balance within the striatum.</p><p>Clinically, Parlodel improves tremor, rigidity, bradykinesia and other parkinsonian symptoms (e.g. depressive symptoms) at all stages of the disease. The therapeutic effect is normally maintained for years (good results have been reported in patients treated for up to 8 years). Parlodel can be given alone in both early and advanced-stage disease, or in combination with other antiparkinsonian drugs. Combination with levodopa results in an enhanced antiparkinsonian effect and frequently enables the levodopa dose to be reduced. Parlodel offers particular benefit to patients exhibiting a deteriorating therapeutic response to levodopa treatment or with complications such as abnormal involuntary movements (choreoathetoid dyskinesia and/or painful dystonia), end-of-dose failure, and &quot;on-off&quot; phenomenon.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>Bromocriptine is rapidly and readily absorbed following oral administration. Peak plasma levels are reached within 1-3&nbsp;hours. The absorption half-life in healthy volunteers is 0.2-0.5&nbsp;hours. An oral dose of 5&nbsp;mg bromocriptine results in a C<sub>max</sub> of 0.465&nbsp;ng/ml.</p><p><em>Concomitant food intake has no relevant effect on bromocriptine exposure. However, it is recommended to always take Parlodel together with food to improve gastrointestinal tolerability.</em></p><p><em>Distribution</em></p><p>Plasma protein binding is 96%.</p><p><em>Metabolism</em></p><p>Bromocriptine is almost completely metabolised in the liver to inactive metabolites. The metabolite profile is complex. Bromocriptine shows a high affinity for CYP3A4, and hydroxylation at the proline ring constitutes a major metabolic pathway.</p><p><em>Elimination</em></p><p>Bromocriptine is eliminated in the form of parent drug and metabolites in bile; only 6% of the drug is eliminated via the kidneys. The elimination half-life is 3-4&nbsp;hours for the parent substance and 50&nbsp;hours for the metabolites.</p><p><em>Pharmacokinetics in special populations</em></p><p><em>Children and adolescents</em></p><p>The pharmacokinetics of bromocriptine have only been investigated in adults.</p><p><em>Elderly patients</em></p><p>The effect of age on the pharmacokinetics of bromocriptine and its metabolites has not been evaluated.</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>The pharmacokinetics of bromocriptine have not been evaluated in patients with hepatic impairment. In patients with hepatic impairment, bromocriptine elimination may be delayed and plasma levels may be increased (see &quot;Dosage/Administration&quot;).</p><p><em>Renal impairment</em></p><p>The effect of renal function on the pharmacokinetics of bromocriptine has not been evaluated (see &quot;Dosage/Administration&quot;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data for Parlodel (bromocriptine) reveal no evidence of any special hazard for humans based on conventional studies of safety pharmacology, single and repeated dose toxicity, genotoxicity, mutagenicity, carcinogenic potential and reproductive toxicity.</p><p>Effects in preclinical studies were observed only at doses x&nbsp;times higher than the maximum doses recommended in humans, indicating little relevance to clinical use.</p><p>Uterine carcinomas were observed in preclinical rat studies at high dosages only. They are considered to be due to the species-specific sensitivity of the test animals to the pharmacological activity of bromocriptine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Silica Colloidal Anhydrous</p><p>Disodium edetate</p><p>Magnesium stearate</p><p>Maleic acid</p><p>Maize starch pregelatinized</p><p>Maize starch</p><p>Lactose monohydrate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protect Parlodel tablets from light and store below 25&deg;C.</p><p>Keep out of the reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Glass bottle.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                approved by Novartis Pharmaceutical Company in 01/2013
 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>